Ashleyk, I agree with jeffreyn about this.

FK-506, as a calcineurin inhibitor, was approved by the FDA as an immunosuppressant for people with organ transplants in 1994.

That means that Phase 1 clinical trials (using healthy volunteers to look at dosages, clearance rates, adverse side-effects, etc) will have been done.

Because of that, proceeding to Phase 2 clinical trials for FK-506 and maybe other immunosuppressants in people with PD should be easy, subject to funding and regulatory approval. In a Phase 2 trial a relatively small number of people with PD would be given FK-506 in open-label format.

If the results of a Phase 2 trial are encouraging then the next step is a Phase 3 trial (double-blind, placebo-controlled, with many more subjects).

I am not sure about forwarding this thread to third parties. This is because, quoting from something at the bottom of all NT pages, "All posts copyright their original authors.". You may be in breach of copyright by forwarding it - a member of the NT admin team should be able to advise you about this.

The Fox Foundation and others should know about these different phases of clinical trials - good luck with your endeavours on this.